Eisai/Biogen’s Lecanemab Effective Across Endpoints, But Will Safety Limit Use?
CTAD Presentation Is First Detailed Data
Alzheimer’s patients treated with the amyloid protofibril-clearing antibody had slower disease progression compared to placebo, with differences increasing over time. Safety concerns, however, are growing.
